US-based clinical-stage pharmaceutical company, Corbus Pharmaceuticals Holdings intends to raise up to $27.2m in gross proceeds through the private placement of 3.8 million shares of its common stock.

Priced at $7 a share, the offering will be subscribed to by institutional and accredited investors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The proceeds will be used for the clinical development of Resunab, a synthetic oral endocannabinoid-mimetic drug being developed to treat chronic inflammatory diseases, and for general corporate purposes.

US-based biopharmaceutical company Dermira intends to raise $168.5m in gross proceeds from an underwritten public offering of its common stock shares.

The company will offer five million shares priced at $33.7 each, while underwriters have a 30-day option to purchase up to 750,000 additional shares.

The company is focused on developing therapies for dermatology diseases.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"US-based biopharmaceutical company Dermira intends to raise $168.5m in gross proceeds from an underwritten public offering of its common stock shares."

Vycellix and Moffitt Cancer Center have signed a research agreement to further validate the former’s novel product candidates, VY-OZ and VY-X, for the potential enhancement of the potency of adoptive cell immunotherapies for cancer.

Vycellix is a US-based biopharmaceutical company, whereas Moffitt Cancer Center is a comprehensive cancer centre based in Sarasota, US.

Italian biotechnology company MolMed and Rocket Pharmaceuticals have entered an agreement to develop gene therapy products for the treatment of Fanconi Anemia.

The lentiviral vectors to be used for the ex-vivo transduction of hematopoietic stem cells will be developed by the former, as part of the agreement. The lentiviral vectors are part of the manufacturing process of the latter Rocket Pharmaceuticals‘ cellular therapy products.

Arrakis Therapeutics has completed a series A venture financing round led by Canaan Partners and participated by Advent Life Sciences, Pfizer, Celgene Corporation, Osage University Partners and Henri Termeer.

The company has raised $38m from the round, with the intention of funding the advancement of its proprietary discovery platforms.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact